Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Small-cell lung cancer in 2016

Shining light on novel targets and therapies

Nature Reviews Clinical Oncology volume 14, pages 75–76 (2017)Cite this article

Subjects

In 2016, the pace of biological insights into small-cell lung cancer (SCLC) was reflected in new treatment approaches that have suggested meaningful clinical benefit to patients. We focus on three highlights of 2016: preclinical studies defining NFIB as a putative driver of metastasis, and two clinical studies; one that assessed the efficacy of an agent targeting the Notch ligand DLL3, and the other that explored T-cell checkpoint-blockade therapies targeting PD-1 and CTLA-4.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Denny, S. K. et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell 166, 328–342 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Semenova, E. A. et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients. Cell Rep. 16, 631–643 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wu, N. et al. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer. Oncotarget http://dx.doi.org/10.18632/oncotarget.11583 (2016).

  4. Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, open-label, phase I study. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(16)30565-4 (2016).

  5. Antonia, S. J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883–895 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Dooley, A. L. et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 25, 1470–1475 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl Med. 7, 302ra136 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Reck, M. et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.67.6601 (2016).

  10. Weiskopf, K. et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest. 126, 2610–2620 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charles M. Rudin and John T. Poirier are at the Molecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA,

    Charles M. Rudin & John T. Poirier

  2. and at the Weill Cornell Medical College, New York, New York, USA.,

    Charles M. Rudin & John T. Poirier

Authors
  1. Charles M. Rudin
    View author publications

    Search author on:PubMed Google Scholar

  2. John T. Poirier
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Charles M. Rudin or John T. Poirier.

Ethics declarations

Competing interests

C.M.R. has been a paid consultant regarding oncology drug development for BMS, Celgene, Chugai, Harpoon, and Novartis. J.T.P. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rudin, C., Poirier, J. Shining light on novel targets and therapies. Nat Rev Clin Oncol 14, 75–76 (2017). https://doi.org/10.1038/nrclinonc.2016.203

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.203

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer